Product logins

Find logins to all Clarivate products below.


Sara Al-Zubeidi

Director, Commercial Strategy Consulting Global Pricing and Market Access

Sara Al-Zubeidi is a Director with Clarivate based in London. Sara has 7+ years commercial strategy consulting experience in life sciences, specializing in global pricing and market access.

Sara leads teams for global P&MA engagements on behalf of pharmaceutical and biotechnology companies. Areas of expertise include pricing and access strategy, evidence generation for HTA submission, innovative agreement strategy, HTA landscape analysis, analogue assessments, value proposition/story development and payer objection handling/negotiation tactics. She also has extensive experience in commercial opportunity assessments, including indication and opportunity prioritization and patient flow assessments. Sara has deep expertise across a wide span of therapeutic areas with oncology, orphan/rare diseases, cardiology, renal and metabolic diseases as specialist areas of interest.

Prior to joining consulting, Sara worked in business development specifically for HEOR and Evidence Strategy teams.

Sara has a Master’s degree in Pharmacogenetics and Stratified Medicine at University College of London (UCL) and a BSc (Hons) in Medical Genetics from Queen Mary University of London.

Latest news

News November 6, 2025
Fujifilm Selects IPfolio from Clarivate

Maximizing the value of intellectual property assets to support business growth London, U.K. November 6, 2025. Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that…

News October 30, 2025
Clarivate Pulse of the Library Report Reveals Link Between AI Literacy, AI Implementation and Confidence

Drawing on insights from over 2,000 librarians representing academic, national and public libraries globally, the report offers an up-to-date view of how they are adapting to rapid change London, U.K.,…

News October 29, 2025
Clarivate Reports Third Quarter 2025 Results

— Continued acceleration of organic ACV — — Raises 2025 Revenues Outlook — — Repurchased 11.7 million ordinary shares and repaid $100 million of debt in the third quarter—  …

Related resources

Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization
Five Medtech Trends to Watch in 2025 Five Medtech Trends to Watch in 2025
Blog February 11, 2025
Five Medtech Trends to Watch in 2025
Medical technology Medtech Medtech Resource Center
The trends to watch in 2025 The trends to watch in 2025
Blog January 8, 2025
The trends to watch in 2025